Evolution of the Average Target: Ligand Pharmaceuticals Incorporated

Evolution of the Average Target - Ligand Pharmaceuticals Incorporated

Evolution of the Target Price: Ligand Pharmaceuticals Incorporated

Evolution of the Target Price - Ligand Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Ligand Pharmaceuticals Incorporated

ee7c3e1c9e1e67cbd160ad4.lind0JhvBHYuA9VOLDzueE8cSqxV1qV2u3jS8CGjxW8.-H6So9UhYk9IVrcne0mdCCdFMNoWntUx8BG0k2fBgFijaIW41CY1Txp7gA~c305f586159f2ebd9a5ab811a8b3901a
10-30 Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says MT
10-30 Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $346 From $334, Keeps Outperform Rating MT
10-30 RBC Raises Price Target on Ligand Pharmaceuticals to $357 From $345, Keeps Outperform Rating MT
10-19 BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says MT
10-19 BofA Securities Adjusts Price Target on Ligand Pharmaceuticals to $406 From $388, Maintains Buy Rating MT
09-25 Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target MT
08-07 RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating MT
08-03 Oppenheimer Adjusts Ligand Pharmaceuticals PT to $326 From $285, Maintains Outperform Rating MT
07-15 RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating MT
05-28 BofA Securities Adjusts Ligand Pharmaceuticals Price Target to $266 From $263 MT
05-08 RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating MT
04-28 RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating MT
03-30 RBC Raises Price Target on Ligand Pharmaceuticals to $64 From $48, Keeps Outperform Rating MT
03-11 BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target MT
02-27 Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating MT
12-10 RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating MT
12-09 Citigroup Initiates Ligand Pharmaceuticals at Buy With $270 Price Target MT
11-25 Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says MT
11-10 RBC Raises Price Target on Ligand Pharmaceuticals to $234 From $185, Keeps Outperform Rating MT
11-03 Oppenheimer Raises Price Target on Ligand Pharmaceuticals to $250 From $190, Keeps Outperform Rating MT
25-09-03 Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating MT
25-05-09 Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating MT
25-04-10 Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target MT
25-02-28 Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating MT
25-02-28 RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+17%
+1.38%
-2.22%
+5.69%
-2.05%
+9.32%
-3.71%
+16.57%
-7.27%
+3.98%
Average +3.87%
Weighted average by Cap. +1.99%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
308.79USD
Average target price
361.27USD
Spread / Average Target
+17.00%
High Price Target
406.00USD
Spread / Highest target
+31.48%
Low Price Target
335.00USD
Spread / Lowest Target
+8.49%

Analyst Consensus Detail

Analyst consensus - Ligand Pharmaceuticals Incorporated

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Ligand Pharmaceuticals Incorporated
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ligand Pharmaceuticals Incorporated
  1. Stock Market
  2. Stocks
  3. LGND Stock
  4. Consensus Ligand Pharmaceuticals Incorporated